Jill Broadfoot
Director of Finance/CFO at ATYR PHARMA, INC.
Net worth: 42 770 $ as of 2024-03-30
Profile
Jill M.
Broadfoot currently works at Talphera, Inc., as Independent Director from 2021, Angiocrine Bioscience, Inc., as Director, and aTyr Pharma, Inc., as Chief Financial Officer from 2018.
Ms. Broadfoot also formerly worked at Otonomy, Inc., as Independent Director from 2021 to 2023, Medical Imaging Centers of America, Inc., as Divisional Controller in 1994, Vical, Inc., as Chief Financial Officer, Secretary & Senior VP from 2004 to 2013, DJO Global, Inc., as Vice President-Finance & Controller in 2004, Ernst & Young LLP, as Audit Manager from 1994 to 1999, GW Pharmaceuticals Ltd., as Vice President & Controller from 2016 to 2017, Emerald Health Pharmaceuticals, Inc., as Chief Financial Officer from 2017 to 2018, and Emerald Health Bioceuticals, Inc., as Chief Financial Officer from 2017 to 2018.
Ms. Broadfoot received her undergraduate degree in 1993 from San Diego State University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ATYR PHARMA, INC.
0.03% | 2024-02-29 | 20,821 ( 0.03% ) | 40 601 $ | 2024-03-30 |
TALPHERA, INC.
0.01% | 2023-10-09 | 2,106 ( 0.01% ) | 2 169 $ | 2024-03-30 |
Jill Broadfoot active positions
| Companies | Position | Start |
|---|---|---|
| ATYR PHARMA, INC. | Director of Finance/CFO | 2018-07-29 |
| TALPHERA, INC. | Director/Board Member | 2021-11-19 |
Former positions of Jill Broadfoot
| Companies | Position | End |
|---|---|---|
| OTONOMY | Director/Board Member | 2023-02-14 |
Emerald Health Bioceuticals, Inc.
 Emerald Health Bioceuticals, Inc. BiotechnologyHealth Technology Emerald Health Bioceuticals, Inc. engages in the provision of research and development of cannabis-free nutritional supplements that support the body’s endocannabinoid system (ECS). Its products include Endo Omega, Endo OmegaVegan, Endo Immune, Endo Sleep, Endo Bliss, Endo Calm, Endo Inflame, and Endo Brain. The company was founded on March 27, 2015 and is headquartered in San Diego, CA. | Director of Finance/CFO | 2018-06-30 |
| GW PHARMACEUTICALS PLC | Comptroller/Controller/Auditor | 2016-12-31 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Director of Finance/CFO | 2013-02-28 |
Training of Jill Broadfoot
| San Diego State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| TALPHERA, INC. | Health Technology |
| Private companies | 7 |
|---|---|
| Medical Imaging Centers of America, Inc. | Health Services |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
DJO Global, Inc.
 DJO Global, Inc. Medical SpecialtiesHealth Technology DJO Global, Inc. engages in the development and distribution medical devices for musculoskeletal health, joint reconstruction, vascular health, and pain management. Its product include knee ligament bracing, custom bracing, post-op knee bracing, hip implants, shoulder implants, shoulder bracing, spine bracing, cervical collars, walking braces, and ankle bracing. The company was founded by Mark Nordquist and Ken Reed in 1978 and is headquartered in Lewisville, TX. | Health Technology |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
GW Pharmaceuticals Ltd.
 GW Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology GW Pharmaceuticals Ltd. operates as an intermediate holding company and management company for investments in its subsidiaries. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Emerald Health Bioceuticals, Inc.
Emerald Health Bioceuticals, Inc. BiotechnologyHealth Technology Emerald Health Bioceuticals, Inc. engages in the provision of research and development of cannabis-free nutritional supplements that support the body’s endocannabinoid system (ECS). Its products include Endo Omega, Endo OmegaVegan, Endo Immune, Endo Sleep, Endo Bliss, Endo Calm, Endo Inflame, and Endo Brain. The company was founded on March 27, 2015 and is headquartered in San Diego, CA. | Health Technology |
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Jill Broadfoot
